Formulation, Optimization and Characterization of Ticagrelor Loaded NLCs Formulation

Ticagrelor is a P2Y12 inhibitor for cardiovascular issues and it works by preventing platelet aggregation, thus reducing the risk of thrombotic events. ticagrelor has shown potential benefits in rheumatoid arthritis when combined with methotrexate. Ticagrelor's role in reducing cardiovascular events may be beneficial for patients with rheumatoid arthritis who are at increased risk for cardiovascular issues. The present study was aimed to formulate, optimize and evaluated ticagrelol loaded NLCs using Box-Behnken design was used. The design was implemented to statistically optimise the factors that were independent: drug: lipid ratio (X1), the surfactant concentration (X2), and soy lecithin concentration (X3), as well as to investigate the main effect, interaction effects, and quadratic effects of these formulation-ingredients on the dependent (response) factor: Entrapment Efficiency (Y1) and in-vitro% drug release (Y2). The independent variables and by combining the above components in variable concentrations (levels), 14 batches were created and evaluated based on the response.